Pilot Clinical Trials of Pharmacotherapies for Substance Related Disorders (R01)

The summary for the Pilot Clinical Trials of Pharmacotherapies for Substance Related Disorders (R01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Pilot Clinical Trials of Pharmacotherapies for Substance Related Disorders (R01): Purpose. The purpose of this FOA is to support pilot clinical studies of medications for investigation as possible treatments for Substance Related Disorders (SRDs). Because the purpose of this FOA is to support pilot studies, preliminary studies are not required. This FOA does not support clinical studies of nicotine or alcohol related disorders, except as comorbid disorders with other SRDs. NIDA expects to receive grant applications for clinical research on medications for which some theoretical or limited preclinical or clinical information exists for investigation as possible treatments of individual SRDs, combinations of them (i.e., cocaine and alcohol use, cocaine and cannabis use) or comorbid with other psychiatric disorders, but which are not ready to be tested in a large and expensive randomized clinical trial. This FOA will not accept proposals that involve preclinical studies. NIDA will not accept applications testing medications that have already demonstrated safety and efficacy for the target disorder. Therefore, there must be a strong rationale for the medications proposed for testing, but no preclinical or clinical data are required or expected.

Federal Grant Title:	Pilot Clinical Trials of Pharmacotherapies for Substance Related Disorders (R01)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health Education
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-DA-09-005
Type of Funding:	Grant
CFDA Numbers:	93.279
CFDA Descriptions:	Drug Abuse and Addiction Research Programs
Current Application Deadline:	No deadline provided
Original Application Deadline:	Oct 23, 2008
Posted Date:	Jun 12, 2008
Creation Date:	Jun 12, 2008
Archive Date:	Nov 23, 2008
Total Program Funding:	$3,000,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Special district governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments Native American tribal governments (Federally recognized) Private institutions of higher education Public housing authorities/Indian housing authorities City or township governments State governments Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled "Additional Information on Eligibility" for clarification) Independent school districts Small businesses Public and State controlled institutions of higher education For profit organizations other than small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER Webmaster
[email protected]
[email protected] If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical ...; • Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...; • Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Tr...; • Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial option...; • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards; • Drug Abuse Aspects of Hiv/Aids and Other Infections; • Epidemiology of Drug Abuse
More Grants from the National Institutes of Health: • SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies...; • Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Al...; • Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional); • Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial No...; • Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimenta...